Clinical Trial: CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07586267) titled 'CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease' on May 07.

Brief Summary: This is an exploratory, open-label, single-arm clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219CX. QT-219CX is a universal allogeneic chimeric antigen receptor T-cell (CAR-T) product targeting both CD19 and BCMA. The study targets subjects with refractory B-cell-related autoimmune diseases, including systemic lupus erythematosus (SLE), multi-drug resistant nephrotic syndrome (NS), IgA nephropathy (IgAN), systemic sclerosis (SSc), and ANCA-associated vasculitis (AAV) .The research is divided into two phases...